Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
(2017).
Are statins 'IDEAL' for non-alcoholic fatty liver disease?.
Curr Med Res Opin. 30(2), 229-31.
(2014). Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention..
Curr Med Res Opin. 30(1), 55.
(2014). Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients..
Curr Med Res Opin. 29(7), 791-2.
(2013). Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property"..
Dig Liver Dis. 45(1), 82-3.
(2013). Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration..
Br J Cancer. 109(2), 332-41.
(2013).
(2013).
(2013). Adipokines: a novel link between adiposity and carotid plaque vulnerability..
Eur J Clin Invest. 42(12), 1278-86.
(2012). Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis..
Angiology. 63(5), 358-66.
(2012). Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study..
J Hum Hypertens. 26(10), 577-84.
(2012). Postoperative adhesion prevention using a statin-containing cellulose film in an experimental model..
Br J Surg. 99(3), 423-9.
(2012).
(2012). Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study..
Curr Med Res Opin. 27(8), 1659-68.
(2011). Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study..
Int J Clin Pract. 65(6), 679-83.
(2011). Impact of statins on glucose metabolism--a matter of debate..
Am J Cardiol. 107(12), 1866.
(2011). Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization..
J Vasc Surg. 51(1), 114-21.
(2010). Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?.
Curr Opin Cardiol. 25(4), 406-10.
(2010). Atorvastatin: safety and tolerability..
Expert Opin Drug Saf. 9(4), 667-74.
(2010). Beneficial changes of serum calcification markers and contralateral carotid plaques echogenicity after combined carotid artery stenting plus intensive lipid-lowering therapy in patients with bilateral carotid stenosis..
Eur J Vasc Endovasc Surg. 39(3), 258-65.
(2010). Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence..
Angiology. 61(2), 137-44.
(2010). A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer..
Cancer Chemother Pharmacol. 65(4), 649-60.
(2010).
(2010).
(2009).
(2009).